Patient-reported Effects of Fedratinib, an Oral, Selective Inhibitor of Janus Kinase 2, on Myelofibrosis-related Symptoms and Health-related Quality of Life in the Randomized, Placebo-controlled, Phase III JAKARTA Trial

Patient-reported Effects of Fedratinib, an Oral, Selective Inhibitor of Janus Kinase 2, on Myelofibrosis-related Symptoms and Health-related Quality of Life in the Randomized, Placebo-controlled, Phase III JAKARTA Trial

Patients with myelofibrosis (MF) experience an array of symptoms that impair health-related quality of life (HRQoL). Fedratinib, an oral, selective Janus-kinase 2 (JAK2) inhibitor, was investigated in the randomized, placebo-controlled, phase III JAKARTA study in adult patients with intermediate- or...

Full description

Bibliographic Details
Main Authors: Ruben A. Mesa, Nicolaas Schaap, Alessandro M. Vannucchi, Jean-Jacques Kiladjian, Francesco Passamonti, Sonja Zweegman, Moshe Talpaz, Srdan Verstovsek, Shelonitda Rose, Pranav Abraham, Jennifer Lord-Bessen, Derek Tang, Shien Guo, Xiaomei Ye, Claire N. Harrison
Format: Article
Language:English
Published: Wiley 2021-05-01
Series:HemaSphere
Online Access:http://journals.lww.com/10.1097/HS9.0000000000000553

Internet

http://journals.lww.com/10.1097/HS9.0000000000000553

Similar Items